Jakafi 15 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZE0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,166
Award facts
- Contract value 100% obligated
- $25,165.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $25,165.90 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 60 tablets of Jakafi 15 mg. The delivery order, issued on January 6, 2026, with an ultimate completion date of January 7, 2026, contains no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025, with a $499.999 billion ceiling value through December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier for Department of Defense healthcare operations, authorized to deliver firm fixed-price orders for branded and generic prescription drugs, biologics, and medical consumables to support military healthcare facilities worldwide. The company's extensive product portfolio encompasses oncology treatments, immunosuppressants, vaccines, specialty pharmaceuticals, and routine medications across multiple therapeutic categories. The PPV-G GEN V represents a $30.3 billion acquisition strategy with multiple regional prime vendor contractors, positioning DMS Pharmaceutical Group as one of several key suppliers supporting the recurring medical supply needs of the federal military medical system across the globe.
Quick answers
Who was awarded contract SPE2DR26FCZE0?
SPE2DR26FCZE0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FCZE0 worth?
The government has obligated $25,166 on SPE2DR26FCZE0.
Is contract SPE2DR26FCZE0 an order under another contract?
Yes. SPE2DR26FCZE0 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZE0 competed?
The extent of competition for SPE2DR26FCZE0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award